Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 10:39:00 06/03/2026 pm IST			5-day change	1st Jan Change
127.80 ^USD	-1.42%		-2.54%	-9.12%

04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM
13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT

Transcript : Neurocrine Biosciences, Inc., Q1 2025 Earnings Call, May 05, 2025

Published on 05/06/2025 at 01:31 am IST - Modified on 06/23/2025 at 11:21 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. [Operator Instructions] Please note, today's call will be

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM
13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT
12/02	Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says	MT
12/02	Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating	MT
12/02	RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating	MT
12/02	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating	MT
12/02	Neurocrine Biosciences, Inc., Q4 2025 Earnings Call, Feb 11, 2026
12/02	Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance	MT
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M	MT
12/02	Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on February 21, 2025.	CI
12/02	Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M	MT
12/02	Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q4 Adjusted EPS $1.88 per Share, vs. FactSet Est of $1.80	MT
12/02	Neurocrine Biosciences, Inc. Provides Product Sales Guidance for the Fiscal Year 2026	CI
26/01	Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia	CI